In the etiology, it has been considered that urinary tract VAs might develop from the cloacal remnants from which the distal colorectum, bladder and urethra originate during embryogenesis. On the other hand, they may also be a product of the chronic irritation-metaplasia-dysplasiacarcinoma sequence [3].
In patients with bladder augmentation cystoplasty, it is reported that the risk of carcinoma development increases [4]. Most of these carcinomas develop in the neobladder or anastomosis line. Only 2 cases of VA that developed from the native bladder mucosa have been reported (Table II) [4,12]. It is thought that the development of VA in patients with bladder augmentation supports the second theory.
We present the first VA case arising in the urethra of a female patient with intestinal bladder augmentation.
She was diagnosed as postrenal acute renal failure. A catheter was inserted and the urea-creatinine levels began to decrease. She had bilateral hydroureteronephrosis. After 4 months, physical examination revealed a carunculalike structure protruding from the urethral meatus. The urinary USG revealed that there was no relation with the bladder. The urethral lesion was excised, and then the bilateral hydroureteronephrosis regressed. CIC was not recommended for postoperative follow-up, as the patient had no residual urine.
The macroscopic examination of the lesion revealed a cream-white colored, fragile and polypoid mass, 4.5x2x1.5 cm in size. Its base was 1.5x1 cm in size, hemorrhagic and brown colored. On the cut sections, it was composed of thin papillary structures adhering to a fibrous core.
On microscopic examination, the tumor consisted of villous structures covered with pseudostratified intestinal type epithelium. Low-grade dysplasia and occasional squamous metaplasia areas were present in the epithelium (Figure 1A-D). All material was investigated and high-grade dysplasia or in-situ / invasive carcinoma was not observed. Immunohistochemical study showed positivity for CK7, CK20, EMA, CEA and CDX2 (Figure 2A-E).
The case was reported as VA of the urethra. The adenomatous epithelium was adjacent to the surgical margin. However, there was no surgical recurrence in the 28-month followup. During follow-up, there was no renal dysfunction or hydronephrosis. The patient stated that she was more comfortable after the operation and could urinate.
In the past, various terms have been used to describe these tumors as villous adenoma, tubulovillous adenoma, villous metaplasia of the intestinal type with dysplasia, and enteric adenoma. However, using the villous tumor or villous polyp terms must be avoided because they can lead to confusion with prostatic-type polyps [19].
Urinary tract VAs mostly arise in the urachus, dome, or trigone of the bladder [1,4]. Cases located in the urethra, renal pelvis, and ureter have also been reported [6,20-22]. Dong et al. have reported that they found only 8 cases of pelvic VA in the English literature and presented 2 additional cases [22]. Qin et al. also reported that they found only 11 cases with urethral VA between 1981 and 2003. Six of these, and the case which they presented, were female [6]. Our presented case is therefore the eighth VA case arising in the female urethra, as far as we are aware.
Two possibilities have been reported in the etiology of VAs. According to the first theory, the distal colorectum, bladder and urethra originate from the cloacal tissue during embryogenesis, and these tumors may develop from the cloacal remnants. This also explains the morphological and cytogenetic similarity of the urinary tract lesions and their counterparts in the gastrointestinal system. According to the second theory, VAs are a product of the irritationmetaplasia- dysplasia-carcinoma sequence [3]. Intestinal metaplasia of the urinary tract is often associated with chronic inflammation, in particular infection, stones and chemical injury [16]. The presence of neutral mucins, acidic sulfomucins, and sialomucins in both cystitis glandularis and VA, and the similar genetic characteristics in the dysplastic regions of the metaplastic mucosa and VA support this theory [3,23].
Augmentation cystoplasty using the colon, ileum or stomach is an accepted reconstructive option for patients with intractable incontinence and poor bladder compliance due to neurogenic and non-neurogenic disorders [6]. However, it has been reported that the risk of developing bladder carcinoma increases 7-8 times with ileum and colon segments, and 14-15 times with gastric segments [4,12]. The most common histologic types are adenocarcinoma and urothelial carcinoma [12]. The incidence of VAs after cystoplasty is very low and most of them develop in the neobladder or anastomosis line [24]. To our knowledge, only 2 cases of VAs originating from the native bladder mucosa have been reported [4,12]. It is thought that the development of bladder VA in patients with a history of augmentation supports the irritation-metaplasia-dysplasiacarcinoma sequence theory [4,12].
Our presented case had a history of intestinal augmentation cystoplasty 30 years ago. However, VA had developed in the urethral mucosa and protruded from the urethral meatus. USG revealed that there was no relation with the bladder. Our case is the first VA in a female urethra with a bladder augmentation history. This case could also be another example supporting the second theory.
Histologically, VAs consist of long villoglandular structures with a central fibrovascular core and these structures are lined by pseudostratified columnar epithelium [1,13]. The epithelial cells display nuclear stratification, crowding, hyperchromasia and occasional prominent nucleoli. Variable mitotic figures are seen in situ and in the invasive component [1]. There is frequently a background of chronic cystitis and association with intestinal/squamous metaplasia, cystitis cystica and cystitis glandularis [2].
Two-thirds of the cases may have simultaneous malignant tumors such as urothelial carcinoma, and in situ or infiltrative adenocarcinoma [2]. Therefore, all of the excision material should be examined carefully [2]. In our case, we investigated all excision material and there was no high-grade dysplasia or in situ/invasive carcinoma focus.
Immunohistochemically, CK20 positivity was reported at a rate of 100%, while CEA and EMA can be positive. CDX2 positivity is also reported [25]. CK7 positivity is observed in approximately half of the cases [1,3,26]. Our case showed positivity for all these markers.
Distinction from tumor metastasis of adjacent organs such as colon, the female genital system, and the prostate is important. For females with genital system adenocarcinoma, Ca125, ER, PR can be helpful as diagnostic markers [6]. Morphological differential diagnosis between metastatic adenocarcinoma of the gastrointestinal system and urinary tract VAs is impossible. CK7 positivity can support VAs of the urinary tract [3,6]. In the male urethra, morphological features of prostatic ductal adenocarcinoma can easily mimic VA [27]. Expression of prostatic lineage markers such as PSA and PSMA could be helpful to differentiate the two entities [13].
Cytologically, it is difficult to distinguish VAs from other glandular lesions. However, VAs must be considered in the differential diagnosis when many glandular cells or mucinous cells without atypia are recognized in the urine [28].
Excision is curative for pure VAs. Carcinoma transformation and recurrence were not reported in pure cases during a mean follow up of 9.9 years [1]. However, more aggressive treatment may be indicated for the VAs coexisting with a malignant tumor as adenocarcinoma to prevent recurrence and metastasis [1,6]. In VAs of yjr calyx, the adenoma may result in atypical hyperplasia and cancerization due to continuous inflammation stimulation, and surgical resection is therefore recommended [22]. In the ureters, tumor growth with mucus retention may be the main cause of ureteral obstruction, and total excision of the tumor prevents early obstruction [29]. In patients with bladder augmentation, long-term active surveillance is necessary in terms of neoplasia development [12,24]. In our presented case, the urethral tumor was excised. Although the surgical margin was microscopically positive, there was no recurrence in 28-month follow-up.
In conclusion, our case is the first VA arising in the female urethra with a history of bladder augmentation. The present case report supports the irritation-metaplasia-dysplasiacarcinoma sequence theory. Excision is curative for pure VAs. Transformation to carcinoma or recurrence has not been reported. However, there may be an accompanying malignant tumor such as adenocarcinoma, urothelial carcinoma etc. in one-third of the cases. Therefore, all excision material should be examined carefully. Routine endoscopic follow-up should be performed in cases with bladder augmentation. Further studies are needed to establish the nature of urinary tract VAs.
CONFLICT of INTEREST
The authors declare no conflict of interest.
AUTHORSHIP CONTRIBUTIONS
Concept: HD, Design: HD, NU, Data collection or
processing: HD, SC, SC, Analysis or Interpretation: HD,
NU, Literature search: HD, Writing: HD, Approval: NU.
1) Cheng L, Montironi R, Bostwick DG. Villous adenoma of the
urinary tract: A report of 23 cases, including 8 with coexistent
adenocarcinoma. Am J Surg Pathol. 1999;23:764-71.
2) Seibel JL, Prasad S, Weiss RE, Bancila E, Epstein JI. Villous
adenoma of the urinary tract: A lesion frequently associated with
malignancy. Hum Pathol. 2002;33:236-41.
3) Fernandes G, Munde S, Rojekar A. Pure Villous Adenoma of the
Vesicoureteric Junction Presenting as Pyonephrosis. J Clin Diagn
Res. 2017;11:ED04-ED05.
4) Nayak A, Depasquale B, Vergara N, Guzzo TA, Lal P. Villous
adenoma arising in the native bladder mucosa and the upper
urinary tract with coexisting neuroendocrine carcinoma following
augmentation cystoplasty. Int J Surg Pathol. 2019;27:450-6.
5) Atik E, Akansu B, Davarci M, Inci M, Yalcinkaya F, Rifaioglu M.
Villous adenoma of the urinary bladder: Rare location. Contemp
Oncol (Pozn). 2012;16:276-7.
6) Qin LF, Liang Y, Xing XM, Wu H, Yang XC, Niu HT.
Villous adenoma coexistent with focal well-differentiated
adenocarcinoma of female urethral orifice: A case report and
review of literature. World J Clin Cases. 2019;7:891-7.
7) Noel JC, Fayt I, Aguilar SF. Adenosquamous carcinoma arising
in villous adenoma from female vulvar urethra. Acta Obstet
Gynecol Scand. 2006;85:373-6.
8) Powell I, Cartwright H, Jano F. Villous adenoma and
adenocarcinoma of female urethra. Urology. 1981;18:612-4.
9) Raju GC, Roopnarinesingh A, Woo J. Villous adenoma of female
urethra. Urology. 1987;29:446-7.
10) Howells MR, Baylis MS. Benign urethral villous adenoma. Case
report. Br J Obstet Gynaecol. 1985;92:1070-1.
11) Morgan DR, Dixon MF, Harnden P. Villous adenoma of urethra
associated with tubulovillous adenoma and adenocarcinoma of
rectum. Histopathology. 1998;32:87-9.
12) Lin TP, Chen M, Hsu JM, Sheu JC. Adenocarcinoma arising
from tubulovillous adenoma in a native bladder following
gastrocystoplasty. Pediatr Surg Int. 2014;30:123-6.
13) McKenney JK. Precursor lesions of the urinary bladder.
Histopathology. 2019;74:68-76.
14) Sung W, Park BD, Lee S, Chang SG. Villous adenoma of the
urinary bladder. Int J Urol. 2008;15:551-3.
15) Karnjanawanichkul W, Tanthanuch M, Mitarnun W, Pripatnanont
C. Renal pelvic villous adenoma presented with mucusuria:
Report of a case and literature review. Int J Urol. 2013;20:247-9.
16) Hudson J, Arnason T, Merrimen JL, Lawen J. Intestinal type villous
adenoma of the renal pelvis. Can Urol Assoc J. 2013;7:E138-42.
17) Pal DK. Villous adenoma of the urinary bladder. J Cancer Res
Ther. 2015;11:665.
18) Kato Y, Konari S, Obara W, Sugai T, Fujioka T. Concurrence of
villous adenoma and non-muscle invasive bladder cancer arising
in the bladder: A case report and review of the literature. BMC
Urol. 2013;13:36.
19) Tamboli P, Ro JY. Villous adenoma of urinary tract: A common
tumor in an uncommon location. Adv Anat Pathol. 2000;7:79-84
20) Fernando Val-Bernal J, Torío B, Mayorga M, García-Arranz P,
Garijo MF. Concurrent tubulovillous adenoma and transitional
cell carcinoma associated with diffuse gastric and intestinal
metaplasia of the defunctioned ureter. Pathol Res Pract.
2001;197:507-13.
21) Bhat S, Chandran V. Villous adenoma of the renal pelvis and
ureter. Indian J Urol. 2010;26:598-9.
22) Dong C, Yang Y, Wu S, Chen G. Clinicopathological analysis of
two cases with pelvis villous adenoma and review of relevant
literature. J Cancer Res Ther. 2015;11:663.
23) Channer JL1, Williams JL, Henry L. Villous adenoma of the
bladder. J Clin Pathol. 1993;46:450-2.
24) Hayashi Y, Shiyanagi S, Nagae I, Ishizaki T, Kasuya K, Katsumata
K, Yamataka A, Tsuchida A. A case of tubular adenoma developing
after bladder augmentation: Case report and literature review. Int
J Surg Case Rep. 2016;19:17-20.
25) Wang J, Manucha V. Villous adenoma of the urinary bladder: A
brief review of the literature. Arch Pathol Lab Med. 2016;140:91-3.
26) Nakamura Y, Orikasa K, Fujishima F, Shibahara Y, Saito R,
Ohkubo T, Ueno S, Sasano H. A case of villous adenoma of the
urinary bladder with tubulovillous architecture: Characterization
by immunohistochemical analysis. Pol J Pathol. 2011;62:179-82.
27) Sato K, Tachibana H, Tsuzuki T, Ueda Y, Katsuda S. Prostatic
ductal adenocarcinoma mimicking villous adenoma of the
urethra. Virchows Arch. 2006;449:597-9.